← All trials
NCT03820817
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2019
- Primary completion
- Nov 30, 2020
- Completion date
- Nov 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 48
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Emory UniversityLead sponsor
- Emory UniversityOverall official - principal investigator
- Emory UniversityReponsible party - principal investigator
- The Leukemia and Lymphoma SocietyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.